Anti-GP107/ GPR107/ GCDRP monoclonal antibody

Anti-GP107/ GPR107/ GCDRP antibody for FACS & in-vivo assay

Target products collectionGo to GPR107/GPR107 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0498-Ab-1/ GM-Tg-hg-MP0498-Ab-2Anti-Human GPR107 monoclonal antibodyHuman
GM-Tg-rg-MP0498-Ab-1/ GM-Tg-rg-MP0498-Ab-2Anti-Rat GPR107 monoclonal antibodyRat
GM-Tg-mg-MP0498-Ab-1/ GM-Tg-mg-MP0498-Ab-2Anti-Mouse GPR107 monoclonal antibodyMouse
GM-Tg-cynog-MP0498-Ab-1/ GM-Tg-cynog-MP0498-Ab-2Anti-Cynomolgus/ Rhesus macaque GPR107 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0498-Ab-1/ GM-Tg-felg-MP0498-Ab-2Anti-Feline GPR107 monoclonal antibodyFeline
GM-Tg-cang-MP0498-Ab-1/ GM-Tg-cang-MP0498-Ab-2Anti-Canine GPR107 monoclonal antibodyCanine
GM-Tg-bovg-MP0498-Ab-1/ GM-Tg-bovg-MP0498-Ab-2Anti-Bovine GPR107 monoclonal antibodyBovine
GM-Tg-equg-MP0498-Ab-1/ GM-Tg-equg-MP0498-Ab-2Anti-Equine GPR107 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0498-Ab-1/ GM-Tg-hg-MP0498-Ab-2; GM-Tg-rg-MP0498-Ab-1/ GM-Tg-rg-MP0498-Ab-2;
GM-Tg-mg-MP0498-Ab-1/ GM-Tg-mg-MP0498-Ab-2; GM-Tg-cynog-MP0498-Ab-1/ GM-Tg-cynog-MP0498-Ab-2;
GM-Tg-felg-MP0498-Ab-1/ GM-Tg-felg-MP0498-Ab-2; GM-Tg-cang-MP0498-Ab-1/ GM-Tg-cang-MP0498-Ab-2;
GM-Tg-bovg-MP0498-Ab-1/ GM-Tg-bovg-MP0498-Ab-2; GM-Tg-equg-MP0498-Ab-1/ GM-Tg-equg-MP0498-Ab-2
Products NameAnti-GPR107 monoclonal antibody
Formatmab
Target NameGPR107
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-GPR107 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species GP107/ GPR107/ GCDRP VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0498
    Target NameGPR107
    Gene ID57720,277463,311857,716428,480694,101096770,617309,100069840
    Gene Symbol and Synonyms9930033D15Rik,bA138E2.2,C530034M11,GCDRP,GPR107,LUSTR1,mKIAA1624
    Uniprot AccessionQ5VW38,D3ZWZ9
    Uniprot Entry NameGP107_HUMAN,GP107_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000148358
    Target ClassificationGPCR

    The target: GPR107, gene name: GPR107, also named as GCDRP, LUSTR1, bA138E2.2. Predicted to enable clathrin heavy chain binding activity. Predicted to be involved in clathrin-dependent endocytosis. Located in Golgi apparatus and nucleoplasm. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.